Revolutionizing Gene Therapy: Viralgen’s Pro10™ Cells and their Role in Scalable AAV Production

A Pro10 Cell Line: Proprietary Mammalian Suspension Technology for Scalable rAAV Production

Viralgen utilizes the Pro10™ cells as the core of a reliable and scalable rAAV vector manufacturing process. These cells have been specifically optimized for rAAV production and have successfully been scaled up to 2000L, showcasing consistent and reproducible cell growth rates. They have demonstrated similar productivity levels in both small and large-scale bioreactors and are capable of producing various AAV serotypes.

The Pro10™ cell line is a proprietary mammalian suspension technology that enhances the efficiency and scalability of recombinant adeno-associated virus (rAAV) production for gene therapy manufacturing. The paper focuses on this new technology, which has been fully characterized and licensed for gene therapy development by various biopharmaceutical companies.

These cells play a critical role in Viralgen’s platform process for manufacturing AAV vectors, significantly contributing to the production of innovative gene therapies. For more information about the HEK293 derived animal component-free suspension Pro10™ cell line, access the full PDF detailing its properties, which can help reduce process development time and costs.

Leave a Reply